Log in to save to my catalogue
Log in to save to my catalogue

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

| Ask | Become a Library member

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11651366

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

About this item

Publication information

Publisher

United States: Massachusetts Medical Society

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Women with advanced endometrial cancer that progressed during platinum-containing therapy were randomly assigned to lenvatinib plus pembrolizumab or physician’s choice of chemotherapy (doxorubicin or paclitaxel). The median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overa...

Alternative Titles

Full title

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11651366

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11651366

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2108330

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections